Princess Diana captured on CCTV as she left the Ritz Hotel in Paris shortly before her death in a car crash in 1997.[Reuters] The UK government has finally released a heavily redacted official log detailing the events following the death of Princess Diana in 1997.
SAN DIEGO, April 11, 2017 /PRNewswire/-- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved INGREZZAâ¢ (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).
It works on the discovery, development and commercialisation of drugs used to treat diseases such as diabetes and cancer. Afrezza, a rapid-acting insulin therapy being developed for the control of hyperglycemia in adults with type one or type two diabetes, is the company's lead product candidate. MKC1106 and MKC204 are two other products being developed for the treatment of different types of cancer.